<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00826670</url>
  </required_header>
  <id_info>
    <org_study_id>08-161</org_study_id>
    <nct_id>NCT00826670</nct_id>
  </id_info>
  <brief_title>Enterobacteriaceae Producing Extended-spectrum β-lactamases (ESBL) Decolonization Study</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Geneva</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Geneva</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multidrug-resistant Enterobacteriaceae producing extended-spectrum β-lactamases (hereafter&#xD;
      called ESBLs) have emerged as an important cause of bloodstream infection in hospitalized&#xD;
      patients and urinary tract infections in the community. As is the case with other&#xD;
      multidrug-resistant organisms chronic colonization is frequent, in the case of ESBLs mostly&#xD;
      intestinal and urinary carriage.&#xD;
&#xD;
      To the investigators knowledge no randomized, placebo-controlled clinical trial has been&#xD;
      performed to study the efficacy of a systematic ESBL eradication strategy. Eradication of&#xD;
      ESBL carriage would cause benefits for the individual patient - by reducing the risk of&#xD;
      infection - and for the community - by reducing transmission. Even if eradication turns out&#xD;
      to be impossible, transient suppression of ESBL might reduce the likelihood of transmission&#xD;
      and thus still be beneficial from an ecologic perspective.&#xD;
&#xD;
      The purpose of the proposed study is to test the hypothesis that the administration of a 10&#xD;
      day course of oral antibiotics active against ESBLs can lead to decolonization of ESBL&#xD;
      carriage in hospitalized patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of eradication of carriage with ESBL-producing Enterobacteriaceae at day 28 post-treatment</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">58</enrollment>
  <condition>Enterobacteriaceae Infections</condition>
  <arm_group>
    <arm_group_label>Topical decolonization</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Decolonization</intervention_name>
    <description>Colistin sulphate (50mg 4x/d PO) + Neomycin (250mg 4x/day PO) for 10 days&#xD;
plus In the presence of urinary tract colonization choice of one of the following agents (according to susceptibility profile, creatinine clearance and individual contraindications) Nitrofurantoin (100mg 3x/day PO) or Norfloxacin (400mg 2x/day PO) for 5 days</description>
    <arm_group_label>Topical decolonization</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (Decolonization)</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patients can be enrolled into the study provided that all of the following criteria are&#xD;
        met:&#xD;
&#xD;
          1. Microbiologically documented rectal carriage of ESBL-producing Enterobacteriaceae,&#xD;
             without signs and symptoms of active infection with ESBL-producing Enterobacteriaceae&#xD;
             at any body site&#xD;
&#xD;
          2. Patient must give written informed consent to participate in the study. The informed&#xD;
             consent can be given by the legal representative if necessary.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Women who are pregnant or nursing&#xD;
&#xD;
          2. Active infection&#xD;
&#xD;
          3. Treatment with antimicrobial agents with activity against ESBL-producing&#xD;
             Enterobacteriaceae&#xD;
&#xD;
          4. Contraindication to the use of one of the study drugs (e.g. renal insufficiency with&#xD;
             creatinine clearance &lt; 30 ml/min)&#xD;
&#xD;
          5. Patient already enrolled in another study, or in the present study for a previous&#xD;
             episode&#xD;
&#xD;
          6. Psychiatric disorder or unable to understand or to follow the protocol directions&#xD;
&#xD;
          7. Permanent indwelling urinary catheter that can not be changed&#xD;
&#xD;
          8. Resistance of the ESBL-producing Enterobacteriaceae to one of the study drugs&#xD;
&#xD;
          9. Known hypersensitivity to one of the study drugs&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Geneva Universits Hospitals</name>
      <address>
        <city>Geneva</city>
        <zip>1211</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <study_first_submitted>January 20, 2009</study_first_submitted>
  <study_first_submitted_qc>January 20, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 22, 2009</study_first_posted>
  <last_update_submitted>August 6, 2012</last_update_submitted>
  <last_update_submitted_qc>August 6, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 7, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Geneva</investigator_affiliation>
    <investigator_full_name>Stephen Harbarth</investigator_full_name>
    <investigator_title>Médecin adjoint agrégé, Service Prévention et Contrô- le de l'Infection</investigator_title>
  </responsible_party>
  <keyword>Antibiotic resistance</keyword>
  <keyword>ESBL carriage</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Enterobacteriaceae Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

